Cargando…
Prostate Cancer Screening Second Edition /
More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world's leading experts on prostate cancer detection upda...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2009.
|
| Edición: | 2nd ed. 2009. |
| Colección: | Current Clinical Urology,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-60327-281-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220117235116.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2009 xxu| s |||| 0|eng d | ||
| 020 | |a 9781603272810 |9 978-1-60327-281-0 | ||
| 024 | 7 | |a 10.1007/978-1-60327-281-0 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Prostate Cancer Screening |h [electronic resource] : |b Second Edition / |c edited by Donna Pauler Ankerst, Catherine M. Tangen, Ian M. Thompson. |
| 250 | |a 2nd ed. 2009. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2009. | |
| 300 | |a XVI, 397 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Current Clinical Urology, |x 2197-7208 | |
| 505 | 0 | |a Trends in Prostate Cancer Screening -- Overview of US Prostate Cancer Trends in the Era of PSA Screening -- Trends in Prostate Cancer Screening: Overview of the UK -- Trends in Prostate Cancer Screening: Canada -- Trends in Prostate Cancer Screening - Overview of Europe -- Prostate-Specific Antigen -- Evolution of Prostate-Specific Antigen for Screening -- The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening -- The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy -- Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer -- PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness -- Risk Assessment for Prostate Cancer -- Nomograms for Prostate Cancer -- Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction -- Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator -- Integration of Risk Assessment in Prostate Cancer Screening -- Family History of Prostate Cancer During Rapidly Increasing Incidence -- Recent Biomarkers for Prostate Cancer -- PSA Isoforms: [?2]proPSA Significant Adjunct to Free PSA -- PCA3 -- Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications -- Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case-Control Association Studies -- GSTP1 Hypermethylation for Prostate Cancer Detection -- EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection -- Design and Methodologic Considerations in Biomarker Studies -- Toward a Robust System for Biomarker Triage and Validation - EDRN Experience -- Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification and Prediction -- Pitfalls in Prostate Cancer Biomarker Evaluation Studies -- Building upon Recently Completed and Ongoing Prospective Trials -- Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial -- The Selenium and Vitamin E Cancer Prevention Trial -- PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer -- The European Randomized Study of Screening for Prostate Cancer (ERSPC). | |
| 520 | |a More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world's leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world's experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Urology. | |
| 650 | 0 | |a Epidemiology. | |
| 650 | 0 | |a Medical sciences. | |
| 650 | 0 | |a Medical informatics. | |
| 650 | 1 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Urology. |
| 650 | 2 | 4 | |a Epidemiology. |
| 650 | 2 | 4 | |a Health Sciences. |
| 650 | 2 | 4 | |a Health Informatics. |
| 700 | 1 | |a Pauler Ankerst, Donna. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Tangen, Catherine M. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Thompson, Ian M. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781607612049 |
| 776 | 0 | 8 | |i Printed edition: |z 9781603272803 |
| 776 | 0 | 8 | |i Printed edition: |z 9781627038539 |
| 830 | 0 | |a Current Clinical Urology, |x 2197-7208 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-60327-281-0 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||